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Abstract
Background: The smallest difference to be detected in superiority trials or the largest difference to be ruled out in
noninferiority trials is a key determinant of sample size, but little guidance exists to help researchers in their choice.
The objectives were to examine the distribution of differences that researchers aim to detect in clinical trials and to
verify that those differences are smaller in noninferiority compared to superiority trials.
Methods: Cross-sectional study based on a random sample of two hundred two-arm, parallel group superiority
(100) and noninferiority (100) randomized clinical trials published between 2004 and 2009 in 27 leading medical
journals. The main outcome measure was the smallest difference in favor of the new treatment to be detected
(superiority trials) or largest unfavorable difference to be ruled out (noninferiority trials) used for sample size
computation, expressed as standardized difference in proportions, or standardized difference in means. Student t
test and analysis of variance were used.
Results: The differences to be detected or ruled out varied considerably from one study to the next; e.g., for
superiority trials, the standardized difference in means ranged from 0.007 to 0.87, and the standardized difference
in proportions from 0.04 to 1.56. On average, superiority trials were designed to detect larger differences than
noninferiority trials (standardized difference in proportions: mean 0.37 versus 0.27, P = 0.001; standardized
difference in means: 0.56 versus 0.40, P = 0.006). Standardized differences were lower for mortality than for other
outcomes, and lower in cardiovascular trials than in other research areas.
Conclusions: Superiority trials are designed to detect larger differences than noninferiority trials are designed to
rule out. The variability between studies is considerable and is partly explained by the type of outcome and the
medical context. A more explicit and rational approach to choosing the difference to be detected or to be ruled
out in clinical trials may be desirable.
Background
A key step in planning a randomized clinical trial is the
determination of the smallest difference in the primary
outcome that should be detected between the study
arms. This difference determines the sample size to be
used in the study together with the type I error, power
and variance of the primary outcome. In principle, this
determination should be made a priori by the research-
ers [1] based on scientific and public health arguments;
only then should the sample size be calculated. In rea-
lity, researchers often start with a small difference to be
detected, which they subsequently revise until an achiev-
able sample size is obtained [2,3]. The danger of such
practice is that trials may end up being sufficiently pow-
ered to detect convenient differences, but underpowered
to detect clinically meaningful differences. On the other
hand, there is currently no objective, scientific method
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for Science and Society. Given this uncertainty, the
description of current practice can provide a useful fra-
mework for judging what differences are large or small.
Stating the smallest difference to be detected is neces-
sary in planning a superiority trial. Planning an equiva-
lence or noninferiority, trial (henceforth called
noninferiority trial) requires a different input: the largest
unfavorable difference that is still compatible with nonin-
feriority. Logically, a noninferiority margin should be
smaller than a superiority margin, other things being
equal, since the former is compatible with equality
between treatments, while the latter excludes equality.
A noninferiority margin that is too wide may lead to the
conclusion that a new treatment is equivalent to the stan-
dard treatment when in fact it is inferior. Of note, an
alternative approach exists for testing noninferiority in
the main outcome at the same time as superiority in a
secondary outcome, such as safety or convenience [4].
There is no consensus regarding the procedures for
choosing a difference to be detected or ruled out. In con-
trast, the type I error rate is often set to 5% and study
power to 80% or 90%. Thus the superiority or noninfer-
iority margin is the main cause of variability in sample
size between trials. In turn, sample size strongly influ-
ences the feasibility and cost of a trial. Surprisingly little
is currently known about the distribution and determi-
nants of differences to be detected or ruled out in trials.
Our main goal was to verify whether superiority mar-
gins used in planning clinical trials are indeed larger on
average than non-inferiority margins used in planning
noninferiority trials, and to examine the variability
between studies in these parameters. Our second goal
was to identify study-related factors that may influence
the choice of the difference, such as the nature of the
study outcome, the clinical field, the type of treatments
compared, etc.
In this article, we reported on a survey of the clinical
important differences used by researchers to estimate
their sample size in 100 randomly selected superiority
trials and 100 noninferiority trials published in 27 lead-
ing medical journals between January 2004 and March
2009. In the “Methods” section, we describe our search
strategy. The data we provide reflects that superiority
trials are designed to detect larger clinical differences
and noninferiority trials ruled out smaller differences;
the variability observed is considerable and may be
partly explained by the medical context and the type of
outcome.
Methods
Study design and sample
We conducted a cross-sectional study based on 200 ran-
domized clinical trials published between January 1
st,
2004 and March 1
st, 2009. We aimed to assess a priori
clinical difference among high-quality, clinically relevant
studies in internal medicine, general practice and mental
health [4]. We therefore performed a search in Medline
(Pubmed) using the following terms [4,5]: “randomized
controlled trial” OR (“randomized” AND “controlled”
AND “trial”), within publication types, subject headings
or text words and restricted our search to trials pub-
lished in 27 medical journals with high impact factors
(Additional file 1). In a second step, in order to retrieve
a sufficient number of noninferiority trials, we added
the keywords “non-inferiority” OR “equivalence” to the
search. We recorded all retrieved citations in a SPSS
database then screened full texts of the articles for elig-
ibility. Among the retrieved studies, we randomly
selected 200 trials.
Eligibility criteria
We included only two-arm, parallel group trials with a
single primary outcome that could be either a continu-
ous or a binary variable. We excluded crossover trials
and cluster-randomized trials which yield paired data
and require specific calculations to estimate the sample
size. We also excluded nonrandomized trials mislabeled
as randomized trials, ancillary analyses of previously
published studies, and studies that used time-to-event
v a r i a b l e sa so u t c o m e s .T w or e a d e r s( A G A ,K B )v e r i f i e d
inclusion and exclusion criteria, and for eligible papers,
extracted relevant data. Uncertainties were discussed
and discrepancies in the assessment of relevant articles
were resolved by consensus.
Data extraction
From the full published report, we recorded the journal,
the year of publication, the medical specialty, the inter-
ventions compared (pharmacological, vaccine, surgical,
medical devices and strategies, including diagnostic,
medical care management, rehabilitative interventions),
the type of primary outcome (dichotomous, continuous)
and whether it was related to mortality or not, whether
the trial was multicenter or not, whether a research
methodologist (statistician or epidemiologist) was asso-
ciated (retrieved from the authors’ affiliation list and
acknowledgement section), whether the trial was sup-
ported by industry, or by another source of funding
(institutional or private grant) or lacking any financial
support. We also classified trials in four subgroups
based on the targeted study population: children below
18 years, mother and child, adults, or elderly. Finally we
made subgroups on the major medical context (cardio-
vascular, infectious diseases or oncology versus other
medical specialties).
Since all articles were published after the revised
CONSORT statement in 2001 [6-8], details of a priori
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collected parameters used for this calculation: type I
error, one or two-tailed test, type II error, and estimated
sample size. For dichotomous outcomes, we retrieved
event proportions in the control and active group (P1,
P2) or treatment effect of interest (difference of propor-
tions). For continuous outcomes, we retrieved the differ-
ence in means (m2 -m 1), and standard deviation, or the
effect size.
Outcomes
When outcomes were expressed as proportions, we cal-
culated a standardized difference in proportions as (P2 -
P1)/√(P(1-P)) where P is the weighted mean of P1 and
P2. This index is analogous to that used for contrasting
two means [9]. When the difference in proportions was
available but proportions in the treatment arms (P1,P 2)
were lacking, P1 and P2 were recalculated using the for-
mulae for sample-size calculation adapted for a c
2 test
or Fisher’s exact test or those adapted for bioequivalence
trials [10,11].
For continuous variables, we calculated the standar-
dized difference in means as the difference of means
divided by the pooled standard deviation: (m2 -m 1)/SD.
When the standard deviation was not given in the meth-
ods section, we used the standard deviation described in
t h er e s u l t ss e c t i o na n dv e r i f i e dt h es a m p l es i z eu s i n g
formulae for the Student’s t test or for bioequivalence
trials [10,11]. In analyses that pooled the two types of
studies, we used the standardized difference in out-
comes, regardless of the type of outcome.
Independent variables
The main predictor was the type of the trial: superiority
versus noninferiority. Other independent variables were:
mortality (single or composite outcome) or not, medical
context (cardiovascular, infectious diseases, oncology, or
other medical specialties), age-group of the study popu-
lation (neonates and children below 18 years of age,
adults and elderly), type of intervention (pharmacologi-
cal versus other), involvement of a statistician/epide-
miologist, year of publication (2004-06 versus 2007-09),
funding source (industry, institution versus no fund or
not stipulated) and finally a single-center or multicenter
recruitment of participants. The target sample size
(≤200, 200-400, 400-800 or >800 participants defined
following quartiles) was also studied in relation to stan-
dardized differences, even though sample size is a conse-
quence of this difference, not its determinant.
Sample size estimation
We sought to detect a moderate difference of the mean
standardized differences between superiority and nonin-
feriority trials, which we defined as half a standard
deviation [12]. This difference would require 84 trials
per group using a power of 90% and a type I error of
5% (two-tailed). We rounded-off the sample size to 100
superiority and 100 noninferiority trials.
Statistical analysis
We first compared the characteristics of the included
superiority and noninferiority trials, using the Mann-
Whitney test for continuous variables and Chi-square or
Fisher’s exact test for categorical variables. Then we
examined the distributions of the standardized differ-
ences in superiority and noninferiority trials, and com-
pared their means using the Student t test. We
performed subgroup analyses, separately for superiority
and noninferiority trials, comparing the standardized
differences according to various study characteristics
using t tests or one-way analysis of variance. We also
tested for interaction between the main effect (superior-
ity/noninferiority type of the trial) and each factor; if the
interaction was not significant, a single P-value for the
factor was presented in the last column of the corre-
sponding Table. Finally we used an analysis of variance
assessing the variance of the standardized differences by
several predictors of interest identified in this prelimin-
ary analysis of variance (noninferiority versus superiority
trials, mortality versus nonmortality trials and the medi-
cal context) and we presented the estimated mean stan-
dardized difference, its standard error and the associated
P-value.
All analyses were performed using SPSS version 17.0
(SPSS Inc., Chicago, Illinois, USA) and Stata IC 11
(STATA Corp., College Station, Texas, USA). Statistical
significance was defined as P < 0.05 (two sided).
Results
Selection of articles
The initial search yielded 6933 citations. We randomly
selected a total of 580 articles in order to obtain our
goal sample of 200 articles that contained information
on the difference to be detected or ruled out (Figure 1).
Of note, for 135 (40.7%) among 334 eligible trials, there
was no value in full reports that described the difference
to detect. Additional file 2 lists the 100 superiority and
100 noninferiority trials included.
Trial characteristics
Superiority and noninferiority trials did not differ in
the journal of publication (Table 1). Justification for
t h ec h o i c eo ft h et r e a t m e n td i f f e r e n c eu s e dw a sf o u n d
at a significantly higher rate in superiority compared
to noninferiority trials. Noninferiority trials dealt more
often with infectious diseases, examined pharmacologic
interventions, and used dichotomous outcomes more
often than superiority trials. Superiority trials were
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ovascular, infectious diseases or oncology (neuro-psy-
chiatry, n = 17; rheumatology, n = 6; internal or
general medicine, n = 4; medical education, n = 3;
other, n = 47). Noninferiority trials required larger
sample sizes, were more often conducted at multiple
centers than superiority trials and were more often
funded by the industry.
Differences used to estimate sample size
In 161 articles (80.5%), the standardized difference in
proportions or in means could be obtained directly from
information provided in the methods section of the arti-
cle. For 39 trials (19.5%), we imputed the standardized
difference in proportions (n = 25) or in means (n = 14)
using additional information (such as the sample size or
observed variance estimates; see Methods).
Overall, the mean standardized difference was 0.45 for
superiority trials and 0.29 for noninferiority trials (Table
2). This difference was seen for standardized differences
in both means (0.56 versus 0.40) and proportions (0.37
versus 0.27). All these differences were statistically sig-
nificant. The spread of standardized difference was
wider in superiority trials than in noninferiority trials
(Figure 2); this is also apparent from the standard devia-
tions of the standardized differences (Table 2).
Trial characteristics associated with clinical differences
used to estimate sample size
Subgroup comparisons of the standardized differences
were conducted separately for superiority and noninfer-
iority trials (Table 3). As expected, smaller detectable
differences were associated with larger sample sizes and
with a multicenter recruitment. Mean detectable differ-
ences were similar across years of publication, the nat-
ure of the intervention (pharmacologic or otherwise),
patient age-groups, statistician involvement, and funding
source, both in superiority and in noninferiority trials.
However studies that used mortality as their primary
outcome used smaller differences than other studies,
again in both types of trials. Trials studying cardiovascu-
lar diseases used lower standardized differences than
infectious diseases or other trials, particularly in noni-
ninferiority trials. We observed the same gradient in
superiority trials but due to smaller sample sizes, there
was no statistical significance.
Analysis of variance confirmed that the standardized
difference was significantly smaller in noninferiority
Figure 1 Flow chart of published randomized-controlled trials considered for inclusion.
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Characteristics Superiority trials
(n = 100)
Noninferiority trials
(n = 100)
P-value*
Journals, No. (%) 0.24**
N Engl J Med 14 (14) 21 (21)
J Clin Oncol 5 (5) 8 (8)
JAMA 6 (6) 10 (10)
Pediatrics 11 (11) 7 (7)
Lancet 10 (10) 4 (4)
Other 54 (54) 50 (50)
Years of publication, No. (%) 0.99
2004-2006 59 (59) 59 (59)
2007-2009 41 (41) 41 (41)
Justification for the treatement difference, No (%) 0.02
Yes (by published or pilot studies) 59 (59) 49 (49)
No 41 (41) 61 (61)
Medical specialty, No (%) <0.001
Cardio-vascular diseases 14 (14) 19 (19)
Infectious diseases 3 (3) 23 (23)
Oncology 6 (6) 10 (10)
Other 77 (77) 48 (48)
Intervention, No. (%) 0.02
Pharmacological 54 (54) 73 (73)
Surgery 8 (8) 3 (3)
Strategy (diagnosis or management) 34 (34) 18 (18)
Other 4 (4) 6 (6)
Patient categories, No. (%) 0.18**.
Adults (including elderly) 77 (77) 82 (82)
Neonates and children < 18 yrs 18 (18) 18 (18)
Mother and child 5 (5) 0 (-)
Primary outcome, No. (%) <0.001
Dichotomous 60 (60) 86 (86)
Continuous 40 (40) 14 (14)
Type of outcome, No. (%) 0.17
Mortality 12 (12) 19 (19)
Other 88 (88) 81 (81)
Statistician/epidemiologist involved, No. (%)
Yes 46 (46) 54 (54) 0.32
No 54 (54) 46 (46)
Median power (interquartile range) 0.80 (0.80-0.90) 0.82 (0.80-0.90) 0.02***
Multicenter trial, No. (%) 0.001
Yes 67 (67) 86 (86)
No 33 (33) 14 (14)
Median sample size (interquartile range) 248 (118-633) 500 (300-900) <0.001***
Funding source, No. (%) 0.004**
Study supported by the industry 50 (50) 70 (70)
Study supported by institutional funds 33 (33) 25 (25)
No funding source or not stipulated 17 (17) 5 (5)
* Comparisons between superiority and noninferiority trials, ** Fisher’s exact test, *** Mann-Whitney test.
Gayet-Ageron et al. BMC Medical Research Methodology 2010, 10:93
http://www.biomedcentral.com/1471-2288/10/93
Page 5 of 9compared to superiority trials (adjusted mean 0.26 ±
0.03 vs. 0.39 ± 0.04, P < 0.001), for dichotomous com-
pared to continuous outcomes (0.28 ± 0.02 vs. 0.42 ±
0.05, P < 0.001) and for mortality outcomes (adjusted
mean 0.20 ± 0.05 vs. 0.39 ± 0.03; P = 0.01); furthermore,
standardized differences tended to be higher for infec-
tious diseases trials (0.42 ± 0.06, P = 0.03) and oncology
trials (0.38 ± 0.05, P = 0.13) compared to cardiovascular
diseases (0.24 ± 0.05). The adjusted R-square for this
model was 0.31.
Discussion
In this study of 200 articles published between 2004 and
2009 in 27 leading medical journals, we found that
superiority trials were designed to detect larger differ-
ences than noninferiority trials. On average, trials that
used dichotomous outcomes aimed to detect a mean
standardized difference of 0.37 but to rule out a standar-
dized difference of 0.27; trials that used continuous out-
comes aimed to detect a standardized difference of 0.56
but to rule out a standardized difference of 0.40. Using
Cohen’s rule of thumb [12], superiority trials typically
attempt to detect a medium effect, while inferiority trials
aim to rule out a small to medium effect. This pattern is
consistent with the logical requirement that for a given
clinical issue, a difference between treatments that is
important for clinical or public health decisions should
be greater than a difference that can be deemed compa-
tible with equality. This suggests that, in general, clinical
researchers use reasonable assumptions in determining
the sample size of clinical trials.
We observed a considerable variability of the differ-
ences to detect or to rule out among studies. This may
be justified by the medical context. E.g., smaller differ-
ences may be relevant in noninferiority trials dealing
with cardiovascular diseases than in infectious diseases
or oncology, because cardiovascular disease is the main
cause of mortality worldwide [13]. But patient availabil-
ity may also be a factor: the potential for including
patients with cardiovascular diseases into clinical trials
is grater than for rare diseases, so that researchers can
afford to explore smaller clinical differences. The type of
outcome may also play a role; e.g., mortality is such an
important outcome that trials may justifiably aim to
demonstrate or exclude smaller differences than would
be the case for less crucial events. However, most other
factors that we examined were not associated with the
differences to be detected or ruled out. Much of the
observed variability remains therefore unexplained [14].
The variability in the difference to be detected or
ruled out contrasts with an overwhelming consensus
regarding the other parameters that guide sample size
determination. Customarily, statistical tests are bilateral,
type I error rates are set at 5%, and the desired power is
between 80% and 90%. Thus the main reason why sam-
ple sizes vary at all is the difference to be detected (or
ruled out). Whether a greater standardization of the dif-
ference to be detected is desirable is debatable. On the
one hand, each research question is unique and deserves
specific consideration. E.g.; a 5% improvement in mor-
tality may not have the same relevance in an elderly
population and in children. Any forceful guidelines as to
the difference to be detected may promote an unreflec-
tive, cookie-cutter approach to study design. On the
other hand, the absence of guidelines regarding the dif-
ference to be detected opens the door to carelessness or
even to manipulation. Instead of reflecting on what
w o u l db et h es m a l l e s ti m p o r t a n td i f f e r e n c e( o rt h el a r -
gest unimportant difference), investigators may be
tempted to engage themselves in the “sample size
samba” [2], by retrofitting the expected detectable differ-
ence to the available number of participants. Future
Table 2 Mean (±SD) standardized difference in proportions and in means in superiority and noninferiority trials
Superiority trials Noninferiority trials P value*
Mean (SD) No. Mean (SD) No.
Standardized difference in proportions 0.37 (0.20) 60 0.27 (0.12) 86 0.001
Standardized difference in means 0.56 (0.30) 40 0.40 (0.11) 14 0.006
Standardized difference 0.45 (0.26) 100 0.29 (0.13) 100 <0.001
SD: standard deviation; *Student t test.
Figure 2 Distribution of the standardized differences in
superiority and noninferiority trials.
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bers that can be plugged into sample size formulae, but
rather list the salient parameters of the decision.
Several limitations of our study may be noted. Firstly,
for about 20% of the trials, we recalculated the expected
detectable differences but did not access the parameters
actually used by authors. Secondly, we may have lacked
power for subgroups analyses. As for the generalizability
of our results, we included only two-arm parallel group
trials with a single primary outcome. This may not be
fully representative of all randomized controlled trials.
As we did not perform a systematic review, but rather
focused on trials published in high-profile journals, our
results may not apply to all trials that are published, and
even less to trials that have not been published, or have
not been completed. We chose to use the standardized
differences together (standardized effect sizes and stan-
dardized increments) in order to allow comparability
between continuous and dichotomous outcomes [15].
Finally our study is descriptive, and does not propose a
formal procedure to help researchers in the choice of
differences to be detected or ruled out.
Reaching consensus on how the difference to be
detected or ruled out should be chosen is an important
challenge for clinical researchers. Current thinking
about how results of clinical trials should be interpreted
Table 3 Factors explaining the mean (±standard deviation) of the standardized differences in superiority and
noninferiority trials and single p-value after adjustment on the type of trial
Superiority trials Noninferiority trials P-value*
Standardized
difference
No. P-value Standardized
difference
No. P-value
Year of publication
2004-2006 0.46 (0.23) 59 0.42 0.28 (0.13) 59 0.40 0.72
2007-2009 0.42 (0.30) 41 - 0.30 (0.12) 41 - -
Medical context 0.38 0.001 0.006
Cardiovascular 0.36 (0.22) 14 0.18 (0.09) 19
Infectious diseases 0.51 (0.11) 3 0.33 (0.08) 23
Oncology 0.44 (0.23) 6 0.26 (0.008) 10
Other 0.47 (0.27) 77 0.31 (0.14) 48
Pharmacological trial
Yes 0.44 (0.28) 54 0.76 0.29 (0.12) 73 0.99 0.77
No (other area) 0.46 (0.24) 46 - 0.29 (0.15) 27 - -
Patients age-group 0.43 0.46
Children < 18 yrs 0.51 (0.18) 18 0.31 (0.10) 18 0.41
Adults 0.44 (0.28) 77 0.28 (0.13) 82 -
Elderly 0.35 (0.13) 5 - 0 -
Mortality outcome
Yes 0.28 (0.17) 11 0.02 0.17 (0.09) 17 <0.001 <0.001
No 0.47 (0.26) 89 - 0.31 (0.12) 83 - -
Statistician involved
Yes 0.44 (0.27) 46 0.83 0.28 (0.14) 54 0.64 0.69
No 0.45 (0.26) 54 - 0.29 (0.10) 46 - -
Patients’ recruitment
Multicenter 0.38 (0.21) 67 <0.001 0.28 (0.12) 88 0.02 <0.001
Single-center 0.58 (0.30) 33 - 0.36 (0.16) 12 - -
Funding source 0.18 0.95 0.19
Industry 0.40 (0.22) 50 0.29 (0.12) 70
Institution/private 0.47 (0.32) 33 0.28 (0.14) 25
Not reported/funded 0.53 (0.23) 17 0.29 (0.09) 5
Sample size ≤200 0.67 (0.25) 0.42 (0.10) 37 27 0.38 (0.13) 0.36 (0.09) 10 23
200-400 0.28 (0.07) 14 <0.001 0.28 (0.09) 38 <0.001 **
400-800 0.18 (0.13) 20 0.20 (0.14) 28
>800
*P-value for each factor after adjustment on the type of trial. **There was a significant interaction between superiority/noninferiority type of the trial and sample
size.
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should be detected) may help guide this process. The
minimal clinically importantd i f f e r e n c e( M C I D )i sa n
important starting point. However, this difference typi-
cally varies from one patient to the other according to
baseline risk of event, risk of complications, and indivi-
dual preference [16]; in contrast, a study planner must
settle on a single value. Should he or she select the
mean MCID for a given population, or aim for a lower
threshold, below the MCID of a large proportion (say,
80%) of the patients? Furthermore, researchers may
want to detect smaller differences that would be consid-
ered meaningful for individual decision making. If a trial
aims to demonstrate the potential of a new class of
drugs, even a small effect may be scientifically impor-
tant; a prevention trial may need to overcome the “pre-
vention paradox”, whereby a treatment brings large
benefits to the community but offers little to each parti-
cipating individual [17]. In other trials, researchers may
aim to detect a difference that is larger than the MCID
for most patients, e.g., when testing a very expensive
intervention that would not be deemed cost-effective
unless a large clinical benefit was demonstrated. A bet-
ter consensus regarding the determination of the differ-
ence to be detected or ruled out may improve the
relevance and utility of clinical trials.
Conclusions
We see two lines for further research. One is the explora-
tion of the researchers’ reasoning that leads to the selec-
tion of a specific difference to be detected in a trial. A
previous study has demonstrated a large inter-individual
variability among doctors in their appreciation of the clini-
cal relevance of treatment benefit [18], while another
study has shown large differences between patients and
doctors in the same area [19]. Our study shows that unex-
plained variability exists among published trials. We need
to know what drives this variability in opinion focusing on
medical area. The second line of research is the develop-
ment of a consensus among researchers regarding best
practices in determining the difference to be detected by a
clinical trial, as stated above. We hope that our results
may stimulate interest in these areas.
Additional material
Additional file 1: List of the 27 high-quality and clinical relevant
journals used in the the Pubmed search.
Additional file 2: List of the 200 randomly selected clinical trials.
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